RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2021 > 7 > RECON: FDA halts Pepaxto trials; Pfizer nears $8B in vax sales for Q2

RECON: FDA halts Pepaxto trials; Pfizer nears $8B in vax sales for Q2

Posted 28 July 2021 | By Kari Oakes 

RECON: FDA halts Pepaxto trials; Pfizer nears $8B in vax sales for Q2

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
 
In Focus: US
  • Pfizer sells $7.8 billion in Covid shots in the second quarter, raises 2021 guidance on vaccine sales (CNBC)
  • AstraZeneca castoff draws $123M wager on CXCR2 antagonist as Arena lines up a buyout option (Endpoints)
  • Opinion: US FDA Should Take Its Time With COVID Vaccine BLAs (Pink Sheet)
  • Biden Is Considering A Vaccine Or Testing Mandate For Federal Workers (NPR)
  • White House tells agencies to mandate masks in federal buildings in hot spots (Reuters)
  • Senators Urge HHS to Support Prescription Drug Imports From Canada (FDA News)
In Focus: International
  • EU signs deal with GSK for supply of potential COVID drug (Reuters)
  • Complix and Jiangsu Nhwa to collaborate on treatment of CNS Diseases (Pharmafile)
Coronavirus Pandemic
  • Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show (STAT)
  • AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria (PM Live)
  • In CureVac's failure, a possible verdict on the past (and future) of mRNA vaccines (Endpoints)
  • England scraps quarantine for fully vaccinated U.S., EU arrivals (Reuters)
  • Legal wrangles hold up U.S. vaccine donations to India (Reuters)
  • Early data shows CanSinoBIO’s inhaled COVID-19 vaccine triggers immune response (PharmaTimes)
  • Scientists model 'true prevalence' of COVID-19 throughout pandemic (PNAS)
Pharma & Biotech
  • In halting confirmatory trial for Oncopeptides' accelerated approval, FDA notes increased risk of death (Endpoints) (FDA)
  • Amgen strengthens portfolio with Teneobio buy (Pharmaletter)
  • Deerfield and ARCH back a new $200M SPAC run by California VC firm (Endpoints)
  • Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects (Scrip)
  • Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC (PM Live)
  • Biogen pulled Aduhelm paper after JAMA demanded edits (Axios) (Reuters)
  • Biogen pushes for broad CMS coverage of Alzheimer's drug — while Eli Lilly looks to escape an NCD (Endpoints)
  • Any Medicare Study Requirements For Alzheimer’s Drugs Should Be Time Limited, CMS Told (Pink Sheet)
  • Deep Genomics, now flush with cash, plans to take dozens of RNA therapies to the clinic (Endpoints)
  • AGTC Moves Past Biogen With Ophthalmic Gene Therapy (Scrip)
  • USP, NIST, others collaborate to enable standardisation of AAV quality measurement (EPR)
  • FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022 (Pink Sheet)
  • France issues moratorium on prion research after fatal brain disease strikes two lab workers (Science)
  • Cassidy joins SpringWorks as CMO (Biocentury)
  • Ipsen strengthens its pre-clinical oncology pipeline with BAKX deal (Pharmaletter)
  • GlaxoSmithKline punts a key Zejula combo study in ovarian cancer with added setbacks on ICOS and RSV (Endpoints)
  • Bristol Myers' Opdivo turns the boat around in Q2 as manufacturing issues haunt CAR-T launch (Endpoints)
  • FDA Grants Rare Pediatric Disease Designation to Day One for Treatment of Pediatric Low-Grade Glioma (Rare Daily)
  • Recognizing Hepatitis R&D on World Hepatitis Day (PhRMA)
  • Pharmacoequity: a new goal for ending disparities in U.S. health care (STAT)
  • RARE-X Appoints Charlene Son Rigby as Chief Executive Officer (Rare Daily)
  • RareStone and Tencent Collaborate on Service Ecosystem Focused on Rare Disease Patients in China (Rare Daily)
  • Abeona Reports New Positive Data from Study of Gene Therapy for Sanfilippo Syndrome (Rare Daily)
Medtech
  • GE Healthcare's COVID-19 recovery continues with double-digit growth in imaging, ultrasound (MedTech Dive)
  • BD Closes on 6th Acquisition for Fiscal 2021 (MD+DI)
  • Boston Scientific tops pre-pandemic results in Q2, expects similar trends in H2 (MedTech Dive)
  • Handing Production to the Robots? It’s Getting Cheap and Easy (MD+DI)
  • Designing Medical Devices for Manufacturability: How to Do It and Why You Should (MD+DI)
  • What's Next for Artificial Intelligence and Medical Devices? (MD+DI)
Government, Regulatory & Legal
  • Johnson & Johnson Held In Contempt In Illinois Talc Trial (Law360)
  • US sells Wu-Tang Clan album to cover Shkreli debt (Endpoints)
  • Bio-Rad And 10X Agree To End Patent War (Law360)
  • Ex-FDA Chief Counsel On Relationships, Consensus-Building (Law360)
  • Medical Products Supply Chain Week in Review (JDSupra)
  • Judge Urged To Rethink Ruling Perrigo Hid $1.9B Irish Tax Bill (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
 

 

© 2022 Regulatory Affairs Professionals Society.